SuparnaBonthala(Bonthala)WedamMD

PubMed

• 4 citations
  U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
  , , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Oct 28
• 25 citations
  U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
  , , , , , , , , , , , , , , , , , , , , > ;Clinical Cancer Research. 2021 Oct 28
• 31 citations
  Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor p...
  Jennifer J Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna Wedam, Melanie Royce, Danielle Krol, Christy L. Osgood, Gwynn Ison, Rajeshwari...> ;The Lancet. Oncology. 2021 Oct 14
• 1 citations
  Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Bre...
  Jeremy Mason, Yutao Gong, Laleh Amiri-Kordestani, Suparna Wedam, Jennifer J Gao, Tatiana M. Prowell, Harpreet Singh, Anup Amatya, Shenghui Tang, Richard Pazdur, Peter ...> ;JCO Clinical Cancer Informatics. 2021 Jul 23
• 5 citations
  US Food and Drug Administration regulatory updates in neuro-oncology.
  Gautam U Mehta, Amy Barone, Diana Bradford, Erin Larkins, Janice Kim, Lee Pai-Scherf, Adnan A. Jaigirdar, Mirat Shah, Suparna Wedam, Laleh Amiri-Kordestani, Marc R. Th...> ;Journal of Neuro-Oncology. 2021 Jun 22
• 9 citations
  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.
  Raymond U. Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje, Suparna Wedam, Gwynn Ison, Sol Atienza, Peter De Porre, Tithi Biswas, Jamie N. Holloway, David S. Hong, ...> ;Clinical Cancer Research. 2021 Feb 9
• 27 citations
  FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer
  Mirat Shah, Suparna Wedam, Joyce Cheng, Mallorie H. Fiero, Huiming Xia, Fang Li, Jianghong Fan, Xinyuan Zhang, Jingyu Yu, Pengfei Song, Wei Chen, Tiffany K. Ricks, Xia...> ;Clinical Cancer Research. 2021 Mar 1
• 31 citations
  FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer.
  Suparna Wedam, Lola Fashoyin-Aje, Xin Gao, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Bellinda L King-Kallimanis, Marc R. Theoret, Amna ...> ;Clinical Cancer Research. 2020 Mar 26
• 69 citations
  FDA approval summary: Palbociclib for Male patients with metastatic breast cancer
  Suparna Wedam, Lola Fashoyin-Aje, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Laleh Amiri-Kordestani, Richard Pazdur, Ju...> ;Clinical Cancer Research. 2020 Mar 15
• 161 citations
  CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled a...
  Jennifer J Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam, Harpreet Singh, Laleh Amiri-Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. G...> ;The Lancet. Oncology. 2020 Feb 1
• 36 citations
  Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an...
  Lynn J. Howie, Harpreet Singh, Erik Bloomquist, Suparna Wedam, Laleh Amiri-Kordestani, Shenghui Tang, Rajeshwari Sridhara, Jacqueline Sanchez, Tatiana M. Prowell, Paul...> ;Journal of Clinical Oncology. 2019 Sep 27
• 17 citations
  National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer
  Andrew D. Seidman, Louise Bordeleau, Louis Fehrenbacher, William E. Barlow, Jane Perlmutter, Larry Rubinstein, Suparna Wedam, Dawn L. Hershman, Jennifer Fallas Hayes, ...> ;Journal of Clinical Oncology. 2018 Sep 13
• 13 citations
  US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments
  Suparna Wedam, Julia A. Beaver, Laleh Amiri-Kordestani, Erik Bloomquist, Shenghui Tang, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Geoffrey Kim, Paul G. K...> ;Journal of Clinical Oncology. 2018 Mar 9
• 91 citations
  FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
  Amanda J. Walker, Suparna Wedam, Laleh Amiri-Kordestani, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Wei Chen, Todd R. Palmby, Jeanne Fourie Zirkelbach, Wenta...> ;Clinical Cancer Research. 2016 Oct 15
• 106 citations
  First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
  Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Amna Ibrahim, Robert Justice, Richard Pazdur, Patricia Cortazar> ;Clinical Cancer Research. 2014 Nov 1
• 56 citations
  Inflammatory Breast Cancer: Dynamic Contrast-enhanced MR in Patients Receiving Bevacizumab—Initial Experience
  Arpi Thukral, David Thomasson, Catherine Chow, Reyes Eulate, Suparna Wedam, Sandeep N. Gupta, Betty Wise, Seth M. Steinberg, David J. Liewehr, Peter L. Choyke, Sandra ...> ;Radiology. 2007 Sep 1
• 409 citations
  Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer
  Suparna Wedam, Jennifer A. Low, Sherry X. Yang, Catherine Chow, Peter L. Choyke, David N. Danforth, Stephen M. Hewitt, Arlene Berman, Seth M. Steinberg, David J. Liewe...> ;Journal of Clinical Oncology. 2006 Feb 10
• 5 citations
  Contralateral Breast Cancer: Where Does It All Begin?
  Suparna Wedam, Sandra M. Swain> ;Journal of Clinical Oncology. 2005 Jul 20
• Dynamic contrast enhanced MRI (DCE-MRI) as a potential predictor of clinical response in patients with inflammatory breast cancer (IBC).
  Doshi A, Wedam SB, Thomasson DM, Garcia-Eulate RM, Wise BJ, Yao J, Steinberg SM, Liewehr DJ, Choyke P, Swain SM> ;J. Clin. Oncol.. 2005-06-01
• Effect of bevacizumab and chemotherapy on serum levels of sVCAM-1 in patient with inflammatory and locally advanced breast cancer.
  Denduluri N, Wedam SB, Yang SX, Parr A, Berman A, Steinberg S, Swain SM> ;J. Clin. Oncol.. 2005-06-01
• 167 citations
  Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer
  Jennifer A. Low, Suparna Wedam, James J. Lee, Arlene Berman, Adam Brufsky, Sherry X. Yang, Marianne S. Poruchynsky, Seth M. Steinberg, Nitin Mannan, Tito Fojo, Sandra ...> ;Journal of Clinical Oncology. 2005 Apr 20
• A phase 2 trial of BMS-247550 (ixabepilone), an epothilone B analog, given daily x 5 in breast cancer.
  Low JA, Wedam SB, Brufsky A, Berman A, Croarkin E, Parks R, Steinberg SM, Mannan N, Fojo T, Swain SM> ;J. Clin. Oncol.. 2004-07-15
• A pilot study to evaluate response and angiogenesis after treatment with bevacizumab in patients with inflammatory breast cancer.
  Wedam SB, Low JA, Yang X, Chow C, Berman A, Eulate R, Danforth D, Hewitt SM, Steinberg SM, Swain SM> ;J. Clin. Oncol.. 2004-07-15
• 29 citations
  Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
  William J. Gradishar, S.B. Wedam, M. Jahanzeb, John K. Erban, Steven A. Limentani, K.-T. Tsai, S.R. Olsen, Sandra M. Swain> ;Annals of Oncology. 2005 Aug 1
• Join now to see all